lead in Medical Technology

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

... facilitates the advancement of our existing lead molecules towards a major milestone," said ... advancement of Cognition Therapeutics' pioneering lead molecules that block the activity of the toxic ... will use these funds to test its most promising lead molecules in behavioral models of Alzheimer's ...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... granted a second orphan drug designation to its lead product candidate Fluidosomes(TM)-tobramycin. ... occur in cystic fibrosis patients and can lead to fatal sepsis. The cell envelopes of these ... technology, for the development of its lead product, an inhalable liposomal formulation of ...

ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule

... - Recruitment on Track for ThromboGenics' lead Product for the Non-Surgical Treatment of Eye ... disease and cancer, announces today that its lead product microplasmin, which is in Phase III ... vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... ankylosing spondylitis," said Jurgen Braun, MD, lead physician at the Rheumazentrum Ruhrgebiet, ... of Rheumatology at the Free University of Berlin, lead study investigator. "As seen in this study, the ... manifesting with joint pain and swelling that can lead to joint destruction and debilitation. It is ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... pivotal, Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute ... development path that has the potential to lead to regulatory approval of orBec(R) in both the US ... vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone ...

Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162

... Many currently available diabetes treatments lead to weight gain, a concern for type 2 diabetes ... compared with the glimepiride group. About lead (TM) 3 Extension The LEAD(TM) 3 ... completed the full two-year study period. lead (TM) 3: two-year data Two years ...

Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients

... ) According to Dr. Patricia Sheiner, the lead investigator in this study, "Using ImmuKnow in ... therapy." Dr. Sheiner added that, "ImmuKnow may lead to improved immunosuppression therapy management ... viral markers in 93 renal transplant recipients. lead study investigator, Dr. Kenneth A. Andreoni, ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... encouraged by these data of BAY 73-4506," said lead investigator Professor Tim Eisen, F.R.C.P., PhD, ... carcinoma (CRC). The data were presented by lead investigator Dirk Strumberg, MD, Department of ... risks, uncertainties and other factors could lead to material differences between the actual future ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... chemotherapy-induced neutropenia lead investigator: M. Duh, Analysis Group, Inc., ... factor (GM-CSF, sargramostim) lead investigator: Lynn Spitler, Northern California ... Phase III clinical trial results lead investigator: S. J. Schuster, Abramson Cancer ...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

... Company (MSDC) announced today that its lead compound, MSDC-0160, can improve insulin ... PPAR-sparing TZDs that led us to develop this lead compound and our drug portfolio. These results ... Upjohn Company. "We are pleased that our lead compound performed so well in the Phase IIa ...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

... ). The television segment features the lead investigator of the study, Dr. Peter A. Blume, ... of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a ... that clinical studies even if successful will lead to product advancement or partnering, that our ...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

... that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in ... caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation ... pipeline includes two preclinical programs with lead candidates being developed to treat serious ...

Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG

... has granted the orphan drug designation to its lead product candidate Fluidosomes-tobramycin. This ... drug concentration in the lung, which in turn may lead to higher efficacy and may allow lower doses. ... for the development of its lead product, a clinical stage treatment against ...

Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis

... minimizing "false positive" results that can lead to overtreatment. In response to these ... of its investigational PCA3 assay that could lead to regulatory approval by the U.S. Food and Drug ... ahead with a U.S. clinical trial that could lead to improved patient care." Gen-Probe's ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... anti-PS antibody, which is similar to Peregrine's lead clinical stage antibody bavituximab and extends ... the U.S. Department of Defense. Peregrine's lead PS-targeting antibody bavituximab is currently in ... cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... in Peregrine's anti-PS pipeline. Peregrine's lead anti-PS antibody bavituximab is currently in ... Friedrich, a Peregrine research scientist and lead author of the study. "In data presented at this ... at UT Southwestern Medical Center and lead author of the study, noted, "Dendritic cells are ...

Vantia Therapeutics' Pipeline Continues to Mature

... Vantia Therapeutics' preclinical portfolio. The lead indications for the kallikrein inhibitor ... parts of the body including the airways. It can lead to pain, nausea, vomiting and death ... said, 'Vantia is pleased to report that its two lead drug candidates continue to make clinical ...

Key Protein May Lead to Faster Acting Anti-Depression Drugs

... that the brain protein called p11 could lead pharmaceutical companies to develop ... the therapeutic actions of these drugs may lead to better treatments with fewer side effects." ... into related neurological diseases that can lead to a Parkinson's cure and, through education of ...

CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals

... which supports innovative ideas that may lead to breakthrough improvements in the future of ... supports innovative ideas and projects that may lead to important breakthroughs in health and health ... health care. When it comes to helping Americans lead healthier lives and get the care they need, the ...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

... plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal ... and cardiac symptoms that usually lead to death from cardio-respiratory failure between ... and pulmonary symptoms that usually lead to progressive muscle weakness and respiratory ...

American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'

... Researchers indicated that this repair can lead to reduced hospital stays, increased mobility, a ... normal activities and reported an ability to lead as normal a lifestyle as those who had never ... Local Anesthetics after Shoulder Arthroscopy Can lead to Devastating Loss After ...

Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP

... than April 7, 2009, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on ... the litigation. In order to be appointed lead plaintiff, the Court must determine that the ...

American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks

... than anticipated had vehicles equipped with 12 lead ECGs, devices that diagnose STEMI and other heart ... should receive training on interpreting 12 lead ECGs. Funding is needed for additional 12 lead ECG devices and training. Information ...

February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus

... because too much blood sugar (glucose) can lead to damage inside blood vessel walls. This damage ... and cause narrowing or blockages that can lead to heart attacks or strokes. Having ... to loud noises also can damage hearing and lead to tinnitus. Tinnitus can be caused by something ...

Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis

... a new model for treating resistant bacteria that lead to pulmonary failure in patients with cystic ... both oral and intravenous, according to LiPuma, lead author of the study. In the present study, ... NanoStat(TM) technology platform. The company's lead product candidates are treatments for ...

Study Shows How Defective DNA Repair Triggers Two Neurological Diseases

... apoptosis. "It happens that defects in ATM also lead to a disease similar to ATLD, highlighting the ... mutations in this one DNA repair complex can lead to different neuropathological outcomes," McKinnon said. The findings could also lead to understanding how carriers of the disease ...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

... ) today announced positive progress in its three lead clinical programs for lysosomal storage disorders ... European regulatory agencies that are expected to lead to the commencement of Phase 3 clinical ... to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... Einstein College of Medicine in New York, and lead investigator on the study. "The study suggests ... * The use of DOXIL may lead to cardiac toxicity. Myocardial damage may lead to congestive heart failure and may occur as the ...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... Data Showed Campath May lead to Overall Survival in Patients with Poor ... well to standard chemotherapeutic agents," said lead investigator Michael Fiegl, MD, Department of ... progression-free and overall survival," said lead investigator William G. Wierda, MD, PhD, ...

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

... pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is ... from target identification and validation through lead optimisation to pre-clinical and clinical ... histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. ...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

... data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at ... organization committed to advancing its lead product candidate, voreloxin, in multiple ... may not demonstrate safety or efficacy or lead to regulatory approval; the risk that preliminary ...

Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207

... from in vitro combination studies of Sequella lead TB drug candidate, SQ109, and Tibotec's lead TB drug candidate, TMC207. Both drug candidates ... underway. About SQ109 The company's lead drug candidate, SQ109, completing Phase I ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

... tumors grown in immunocompromised mice -- lead investigator: Allison Berger, Senior Scientist, ... in cultured human tumor cells -- lead investigator: Michael Millhollen, Scientist, ... Phase I study -- lead investigator: J. Tabernero Caturla, Hospital ...

Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs

... the Challenge Investment Program. The company's lead compounds, currently in preclinical testing, aim ... loss in aged mice to young levels. "Our lead compound for Alzheimer's disease may represent ... preclinical studies to further develop our lead agents for clinical trials." Founded in 2004 by ...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

... with this disorder," said Lenard A. Adler, M.D., lead researcher in this study and director of the ... help children and adults diagnosed with ADHD to lead more productive lives." VYVANSE is a ... while taking Vyvanse. Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause ...

Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting

... a preclinical study of RDEA119, the Company's lead mitogen-activated ERK kinase (MEK) ... it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is ... of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in ...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

... a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is ... from target identification and validation through lead optimisation to pre-clinical and clinical ... histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its ...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting

... data will be presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, ... it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is ... of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in ...

Major State Grant Accelerates Research and Development of Novel Cancer Therapy

... from the FDA to perform clinical trials that will lead to drug approval." Weissbach and his team initially identified a lead compound that in combination with an oxidizing ... future success and our ability to lead the way in discoveries that save lives and ...

Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

... patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC). ... of patients annually." TSC is the company's lead candidate in a family of ... atherosclerosis in which arterial blockages lead to decreased leg blood flow. During exercise ...